ストックスクリーナーアプリを入手
2.22
0.45%
0.01
アフターアワーズ：
2.17
-0.05
-2.25%
前日終値:
$2.21
開ける：
$2.21
24時間の取引高:
73,192
Relative Volume:
0.05
時価総額：
$23.11M
収益：
-
当期純損益:
$-45.57M
株価収益率:
-0.3524
EPS:
-6.3
ネットキャッシュフロー:
$-38.56M
1週間 パフォーマンス:
+0.91%
1か月 パフォーマンス:
-12.60%
6か月 パフォーマンス:
+12.12%
1年 パフォーマンス:
-1.33%
1日の値動き範囲:
$2.17
$2.25
1週間の範囲:
$1.94
$2.25
52週間の値動き範囲:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
SABS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.22 | 20.53M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc (SABS) 最新ニュース
Predicting SAB Biotherapeutics Inc. trend using moving averagesJuly 2025 Breakouts & AI Driven Stock Price Forecasts - Newser
Advanced analytics toolkit walkthrough for SAB Biotherapeutics Inc. Equity WarrantEarnings Overview Summary & Expert Approved Momentum Ideas - Newser
What recovery options are there for SAB Biotherapeutics Inc. Equity Warrant2025 Short Interest & Real-Time Volume Trigger Notifications - Newser
What MACD signals say about SAB Biotherapeutics Inc.Weekly Stock Summary & Consistent Profit Trade Alerts - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionQuarterly Earnings Summary & Short-Term High Return Strategies - Newser
Analyzing SAB Biotherapeutics Inc. Equity Warrant with risk reward ratio chartsTrade Volume Summary & High Win Rate Trade Alerts - Newser
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowTrend Reversal & AI Forecast Swing Trade Picks - Newser
Can SAB Biotherapeutics Inc. hit a new high this monthJuly 2025 Earnings & Stepwise Swing Trade Plans - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesInflation Watch & Real-Time Price Movement Reports - Newser
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 3,433.6% in July - Defense World
Brookline Capital Management Weighs in on SABS Q3 Earnings - Defense World
Chart based exit strategy for SAB Biotherapeutics Inc.2025 Macro Impact & AI Powered Market Trend Analysis - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe charts2025 Market Sentiment & Weekly Stock Breakout Alerts - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedMarket Performance Report & Fast Gain Swing Trade Alerts - Newser
What to do if you’re stuck in SAB Biotherapeutics Inc.July 2025 Retail & Reliable Price Breakout Alerts - Newser
Key metrics from SAB Biotherapeutics Inc.’s quarterly dataTrade Ideas & Scalable Portfolio Growth Methods - Newser
Why SAB Biotherapeutics Inc. stock attracts strong analyst attentionWeekly Stock Report & Fast Gaining Stock Reports - Newser
Will SAB Biotherapeutics Inc. stock benefit from interest rate changes2025 Market Outlook & Real-Time Market Trend Scan - Newser
Can swing trading help recover from SAB Biotherapeutics Inc. Equity Warrant lossesProfit Target & AI Enhanced Trading Alerts - Newser
SAB Biotherapeutics Inc. Equity Warrant stock retracement – recovery analysis2025 Top Gainers & Risk Controlled Daily Trade Plans - Newser
Exit strategy if you’re trapped in SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stock2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stock [2025 Breakouts & Breakdowns]AI Driven Stock Reports - Newser
Top chart patterns to watch in SAB Biotherapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantPredictive AI Engine for Smart Investing - Newser
How SAB Biotherapeutics Inc. Equity Warrant stock performs during market volatilityChart Based Entry Tool for ROI Traders - Newser
SAB Biotherapeutics Inc. stock chart pattern explainedFree Pattern Detection for Entry Confirmation - Newser
Can a trend reversal in SAB Biotherapeutics Inc. Equity Warrant lead to recoveryPredictive Screener for Daily Trade Watch - Newser
SAB Biotherapeutics Receives Buy Rating and $5.00 Price Target from Craig-Hallum - AInvest
Technical analysis overview for SAB Biotherapeutics Inc. stockRisk Shielded Trade Watch with Analysis - Newser
Will SAB Biotherapeutics Inc. Equity Warrant continue its uptrendFree Short Term Buy List With Stop Protection - Newser
Predicting SAB Biotherapeutics Inc. Equity Warrant trend using moving averagesSafe Investment Ideas with Growth Upside - Newser
Analyzing net buyer seller activity in SAB Biotherapeutics Inc.Free Trade Setups With Clear Risk Limits - Newser
Sector ETF performance correlation with SAB Biotherapeutics Inc. Equity WarrantTrading Opportunities Forecast by AI Insight - Newser
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedFree Trade Timing Strategy With Technical Data - Newser
Ichimoku Cloud Indicates Uncertainty Around SAB Biotherapeutics Inc.Consistent Income Focused Trade List Analyzed - metal.it
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyAI-Based Reversal Point Prediction Signal - Newser
SAB Biotherapeutics Inc. stock volume spike explainedMinimal Risk Growth Investment Opportunity Analysis - Newser
Chardan Capital Issues Pessimistic Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price - Defense World
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):